Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -299% Improvement Relative Risk c19hcq.org Tamura et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 188 patients in Brazil (March - November 2020) Higher mortality with HCQ (p=0.042) Tamura et al., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8 Favors HCQ Favors control
Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies
Tamura et al., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8
Tamura et al., Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin.., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 188 hospitalized patients in Brazil, showing higher risk of mortality with HCQ. Relatively few patients received HCQ. The results are likely subject to confounding by indication with treatment more likely for severe cases, and severity was not used in adjustments. Confounding by time is likely, with declining use of HCQ and improving SOC over the study period. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
risk of death, 299.0% higher, OR 3.99, p = 0.04, treatment 25, control 163, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tamura et al., 13 Jul 2021, retrospective, Brazil, peer-reviewed, 4 authors, study period 10 March, 2020 - 13 November, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: (2021) 13:76 Tamura et al. Diabetol Metab Syndr https://doi.org/10.1186/s13098-021-00695-8 Diabetology & Metabolic Syndrome Open Access RESEARCH Outcome and death risk of diabetes patients with Covid‑19 receiving pre‑hospital and in‑hospital metformin therapies Rodrigo Esaki Tamura1,3, Said Muhammad Said2,4, Leticia Mussin de Freitas1 and Ileana Gabriela Sanchez Rubio1,2,3* Abstract Background: COVID-19 has stroke Brazil harshly, deaths by COVID-19 in Brazil represent almost 13% of the total deaths by COVID-19 in the world, even though Brazilian population represents only 2.6% of the world population. Our aim in this study was to evaluate death and intubation outcomes and risk factors associated with COVID-19, and treatment options focusing on diabetes patients and the use of metformin pre-admission and during hospitalization. Methods: In this Brazilian single-center study we evaluated 1170 patients hospitalized due to COVID-19. Diabetes patients (n = 188) were divided based on their use of pre-hospital and in-hospital metformin (non-met-group and met-group). Results: In the total cohort most comorbidities were risk factors for orotracheal intubation and death. The use of chloroquine/hydroxychloroquine was significantly associated with increased death and intubation risk in uni- and multivariate analysis. Diabetes patients showed worst clinical feature compared with non-diabetes patients. In-hospital non-met-group had increased mortality (20.5%) compared to met-group (3.5%) (p = 0.0002) and univariable cox proportion hazard regression indicated in-hospital metformin reduced mortality (HR = 0.325, p = 0.035). Patients that used pre-hospital metformin showed lower severity parameters at hospital admission. (met-group: 2.45 ± 2.5; nonmet-group: 4.25 ± 3.4). In all the groups older patients showed more severe clinical conditions and high risk of death and intubation. Conclusion: Even though this is a single-center study, results from other reports have shown a similar trend, indicating that patients that used metformin during hospitalization have a better prognosis and reduced risk of death. Keywords: COVID-19, Diabetes, Metformin, Brazil, Survival Background The COVID-19 pandemic is caused by SARS-CoV-2, a member of the Betacoronavirus genus of the Nidovirales order, its single stranded positive polarity RNA encodes non-structural and structural proteins, one important structural protein is the Spike, which mediates *Correspondence: ilerubio@gmail.com; ileana.rubio@unifesp.br 1 Department of Biological Sciences, Federal University of São Paulo, Rua Pedro de Toledo 669, 11º Andar, Diadema, SP, Brazil Full list of author information is available at the end of the article recognition of the ACE2 cell receptor. The non-structural proteins play pivotal role in cell regulation, that impacts host response to viral infection [1]. Data from the World Health Organization (WHO) points to over 178 million confirmed cases and 3,864,180 deaths until June, 21st 2021 (https://​covid​19.​who.​int/). Deaths by COVID-19 in Brazil has reached the number of 501,825 on June, 21st 2021 (https://​covid.​saude.​gov.​br/). Diabetes is one of the main risk factors for COVID19, promoting a harmful pro-inflammatory state [2]. © The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit